Skip to Main Content

Author Details

Emile E Voest
The Netherlands Cancer Institute
1989
337
75
Trey Ideker (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
38092944Optimized whole-genome sequencing workflow for tumor diagnostics in routine pathology practice.Nat Protoc2024
38006283Impact of genetic counseling strategy on diagnostic yield and workload for genome-sequencing-based tumor diagnostics.Genet Med2024
36450103Multiomics of Colorectal Cancer Organoids Reveals Putative Mediators of Cancer Progression Resulting from SMAD4 Inactivation.J Proteome Res2023
37647492Repurposing drugs in oncology.Clin Adv Hematol Oncol2023
37641393Precision cancer medicine: Concepts, current practice, and future developments.J Intern Med2023
37424386Limited clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials.Int J Cancer2023
37119523Phase II study (KAMELEON) of single-agent T-DM1 in patients with HER2-positive advanced urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma.Cancer Med2023
37054504Single-arm trials supporting the approval of anticancer medicinal products in the European Union: contextualization of trial results and observed clinical benefit.ESMO Open2023
37311414Taxanes trigger cancer cell killing in vivo by inducing non-canonical T cell cytotoxicity.Cancer Cell2023
36621142Identifying somatic changes in drug transporters using whole genome and transcriptome sequencing data of advanced tumors.Biomed Pharmacother2023
36914745Functional precision oncology using patient-derived assays: bridging genotype and phenotype.Nat Rev Clin Oncol2023
36870947Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumours.BMC Cancer2023
36669486Base editing screens map mutations affecting interferon-γ signaling in cancer.Cancer Cell2023
36864254Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer.Nat Med2023
36631610γδ T cells are effectors of immunotherapy in cancers with HLA class I defects.Nature2023
36525971IL-5-producing CD4<sup>+</sup> T cells and eosinophils cooperate to enhance response to immune checkpoint blockade in breast cancer.Cancer Cell2023
36593398Identification of patient-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cell neoantigens through HLA-unbiased genetic screens.Nat Biotechnol2023
34965952Differential Survival and Therapy Benefit of Patients with Breast Cancer Are Characterized by Distinct Epithelial and Immune Cell Microenvironments.Clin Cancer Res2022
35775007A Comparison of Post-marketing Measures Imposed by Regulatory Agencies to Confirm the Tissue-Agnostic Approach.Front Med (Lausanne)2022
35440717Delivering precision oncology to patients with cancer.Nat Med2022
35642948Can Drug Repurposing Accelerate Precision Oncology?Cancer Discov2022
35792649Feasibility of whole-genome sequencing-based tumor diagnostics in routine pathology practice.J Pathol2022
35598186Efficacy and toxicity of vemurafenib and cobimetinib in relation to plasma concentrations, after administration via feeding tube in patients with BRAF-mutated thyroid cancer: a case series and review of literature.Cancer Chemother Pharmacol2022
35489347The DRUG Access Protocol: access inequality and European harmonisation - Authors' reply.Lancet Oncol2022
35716537Trastuzumab and pertuzumab combination therapy for advanced pre-treated HER2 exon 20-mutated non-small cell lung cancer.Eur J Cancer2022
35688159RNF31 inhibition sensitizes tumors to bystander killing by innate and adaptive immune cells.Cell Rep Med2022
36463731Complete genomic characterization in patients with cancer of unknown primary origin in routine diagnostics.ESMO Open2022
35046062Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment.Clin Cancer Res2022
35114116Harmonising patient-access programmes: the Dutch DRUG Access Protocol platform.Lancet Oncol2022
35053600Clinical Impact of Prospective Whole Genome Sequencing in Sarcoma Patients.Cancers (Basel)2022
34373653Limited evolution of the actionable metastatic cancer genome under therapeutic pressure.Nat Med2021
33776923Patient-Derived Organoid Models of Human Neuroendocrine Carcinoma.Front Endocrinol (Lausanne)2021
33887686Prospective experimental treatment of colorectal cancer patients based on organoid drug responses.ESMO Open2021
34957158Extension of Indication for Authorised Oncology Products in the European Union: A Joint Effort of Multiple Stakeholders.Front Med (Lausanne)2021
34515408The Porto European Cancer Research Summit 2021.Mol Oncol2021
34416168Tumor organoids: Opportunities and challenges to guide precision medicine.Cancer Cell2021
34475104Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types.Clin Cancer Res2021
34115988Developing and validating model systems for immuno-oncology.Cancer Cell2021
31518438BTK inhibitors synergise with 5-FU to treat drug-resistant TP53-null colon cancers.J Pathol2020
31853056Tumor organoid-T-cell coculture systems.Nat Protoc2020
33167975Study protocol: Whole genome sequencing Implementation in standard Diagnostics for Every cancer patient (WIDE).BMC Med Genomics2020
32577539Enhancing radiation response by a second-generation TRAIL receptor agonist using a new in vitro organoid model system.Clin Transl Radiat Oncol2020
32685681Learning health care systems: Highly needed but challenging.Learn Health Syst2020
32572029Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours.Nat Commun2020
32749074Towards a cancer mission in Horizon Europe: recommendations.Mol Oncol2020
32312756Preferences to receive unsolicited findings of germline genome sequencing in a large population of patients with cancer.ESMO Open2020
32504042Partner independent fusion gene detection by multiplexed CRISPR-Cas9 enrichment and long read nanopore sequencing.Nat Commun2020
32353785Patients with cancer in the era of 2019 novel coronavirus disease.Eur J Cancer2020
32405058Caring for patients with cancer in the COVID-19 era.Nat Med2020
32375033Challenges in Establishing Pure Lung Cancer Organoids Limit Their Utility for Personalized Medicine.Cell Rep2020
  • 1 - 50 of 337

Recommended Authors

Chad V Pecot
University of North Carolina at Chapel Hill
Career Start Year 2009
Number of shared co-authors 2
Bo Gao
Crown Princess Mary Cancer Centre, Westmead Hospital
Career Start Year 2008
Number of shared co-authors 2
Jordi Rodon
The University of Texas MD Anderson Cancer Center
Career Start Year 2006
Number of shared co-authors 12
Shubham Pant
The University of Texas MD Anderson Cancer Center
Career Start Year 2005
Number of shared co-authors 2
Pavlos Msaouel
The University of Texas MD Anderson Cancer Center
Career Start Year 2004
Number of shared co-authors 2
Philippe L Bedard
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2002
Number of shared co-authors 11
Pingfu Fu
Case Western Reserve University
Career Start Year 2000
Number of shared co-authors 0
David J Liewehr
Center for Cancer Research
Career Start Year 1999
Number of shared co-authors 2
Annette T Byrne
Royal College of Surgeons in Ireland (RCSI)
Career Start Year 1999
Number of shared co-authors 9
Elisabeth I Heath
Karmanos Cancer Center, Wayne State University
Career Start Year 1999
Number of shared co-authors 9
Thomas J George
UF Health Cancer Center
Career Start Year 1998
Number of shared co-authors 7
Sunil Sharma
Brody School of Medicine, East Carolina University
Career Start Year 1997
Number of shared co-authors 6
Jorge Nieva
Norris Comprehensive Cancer Center, University of Southern California
Career Start Year 1995
Number of shared co-authors 0
Wells A Messersmith
University of Colorado Anschutz Medical Campus
Career Start Year 1995
Number of shared co-authors 7
Craig Gedye
Hunter Medical Research Institute, University of Newcastle
Career Start Year 1993
Number of shared co-authors 7
Ramona F Swaby
Merck & Co., Inc.
Career Start Year 1991
Number of shared co-authors 2
Anil K Sood
The University of Texas MD Anderson Cancer Center
Career Start Year 1991
Number of shared co-authors 9
Suresh Nair
Lehigh Valley Topper Cancer Institute
Career Start Year 1990
Number of shared co-authors 3
Joan Albanell
Hospital del Mar Research Institute
Career Start Year 1990
Number of shared co-authors 6
Luc Dirix
GZA Ziekenhuizen Campus Sint-Augustinus, University of Antwerp
Career Start Year 1988
Number of shared co-authors 21
Jose A Lopez-Martin
Hospital Universitario 12 de Octubre
Career Start Year 1988
Number of shared co-authors 2
Alberto Zambelli
IRCCS Humanitas Research Hospital
Career Start Year 1987
Number of shared co-authors 2
Paul Harnett
Westmead Clinical School, University of Sydney
Career Start Year 1986
Number of shared co-authors 3
Kenneth R Hess
The University of Texas MD Anderson Cancer Center
Career Start Year 1986
Number of shared co-authors 5
Stefan Aebi
University of Bern
Career Start Year 1985
Number of shared co-authors 5
Seth M Steinberg
Center for Cancer Research, National Cancer Institute
Career Start Year 1984
Number of shared co-authors 6
Helen J Ross
Mayo Clinic
Career Start Year 1982
Number of shared co-authors 1
Peter J Selby
College of Agriculture and Life Sciences, Cornell University
Career Start Year 1977
Number of shared co-authors 5
James H Doroshow
National Cancer Institute, National Institutes of Health
Career Start Year 1974
Number of shared co-authors 9
Antonio Jimeno
University of Colorado School of Medicine
Career Start Year 1974
Number of shared co-authors 6

Collaborators

Jan H M Schellens
Department of Pharmaceutical Sciences, Utrecht University
Co-authored papers 43
Martijn P Lolkema
Erasmus MC Cancer Institute
Co-authored papers 40
Edwin Cuppen
Hartwig Medical Foundation
Co-authored papers 31
Rachel H Giles
University Medical Center Utrecht
Co-authored papers 24
Stefan Sleijfer
Erasmus MC Cancer Institute, University Medical Center Rotterdam
Co-authored papers 19
Paul J van Diest
University Medical Center Utrecht
Co-authored papers 14
Lodewyk F A Wessels
University Medical Centre Mannheim, University of Heidelberg
Co-authored papers 14
Neeltje Steeghs
Netherlands Cancer Institute-Antoni Van Leeuwenhoek
Co-authored papers 13
Niven Mehra
Radboud university medical center
Co-authored papers 11
Hans Clevers
Princess Maxima Center for Pediatric Oncology
Co-authored papers 7
Gerrit A Meijer
The Netherlands Cancer Institute
Co-authored papers 7
Daniel S Peeper
Netherlands Cancer Institute
Co-authored papers 6
Carlos Caldas
Cancer Research UK Cambridge Institute, University of Cambridge
Co-authored papers 5
John W M Martens
Erasmus Medical Center (MC) Cancer Institute
Co-authored papers 5
Fatima Cardoso
Champalimaud Clinical Center/Champalimaud Foundation
Co-authored papers 4
Oscar Krijgsman
The Netherlands Cancer Institute
Co-authored papers 4
Fabien Calvo
Universite de Paris-Cite
Co-authored papers 4
Anthonius de Boer
Co-authored papers 3
Paul Hamberg
Franciscus Gasthuis & Vlietland Hospital Rotterdam and Schiedam
Co-authored papers 3
Harmen J G van de Werken
Department of Immunology Erasmus University Medical Center
Co-authored papers 3
Job van Riet
Erasmus MC Cancer Institute
Co-authored papers 3
Stefan Fr??hling
German Cancer Research Center (DKFZ), National Center for Tumor Diseases (NCT)
Co-authored papers 3
Andries M Bergman
The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital
Co-authored papers 3
Lillian L Siu
Princess Margaret Cancer Centre, University Ave
Co-authored papers 3
Joachim Sch??z
European Academy of Cancer Sciences
Co-authored papers 2
Jorge S Reis-Filho
Memorial Sloan-Kettering Cancer Center
Co-authored papers 2
Mathew J Garnett
Wellcome Sanger Institute
Co-authored papers 2
Charles L Sawyers
Memorial Sloan Kettering Cancer Center
Co-authored papers 2
Anamaria A Camargo
Hospital Sirio-Libanes
Co-authored papers 2
Jos Jonkers
Oncode Institute, Netherlands Cancer Institute
Co-authored papers 2
Release 1.2